Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial
Official title:
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes an up to 4-week Screening Period, an up to 12-week Washout Period, a 12-week Randomized Treatment Period (Period 1), an up to 24-week Randomized Withdrawal Period (Period 2), an up to 52-week Long-term Extension (LTE) Period (optional), and Safety Follow-up 4 weeks after the last dose of study treatment. The total study duration will be up to approximately 109 weeks. Eligible participants will be assigned to one of four cohorts based upon their baseline CIDP treatment (Cohorts A and D - immunoglobulin [Ig] or plasma exchange [PLEX]; Cohort B - corticosteroids; Cohort C - naive or untreated in previous 3-24 months) and whether they meet diagnosis according to the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria (Cohorts A, B, and C) or clinical criteria only (Cohort D) at the time of screening.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02465359 -
Subcutaneous Immunoglobulin for CIDP
|
N/A | |
| Recruiting |
NCT05584631 -
IVIG vs SCIG in CIDP
|
Phase 1 | |
| Withdrawn |
NCT01236456 -
High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
| Terminated |
NCT03779828 -
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
|
||
| Completed |
NCT01184846 -
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 3 | |
| Recruiting |
NCT05011006 -
NT-3 Levels and Function in Individuals With CMT
|
||
| Recruiting |
NCT06290141 -
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 3 | |
| Completed |
NCT01379833 -
Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
|
||
| Completed |
NCT02414490 -
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
|
||
| Completed |
NCT01545076 -
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
|
Phase 3 | |
| Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
| Recruiting |
NCT04672733 -
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
|
||
| Not yet recruiting |
NCT04480450 -
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
| Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
| Not yet recruiting |
NCT05219383 -
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy
|
||
| Completed |
NCT02111590 -
Immunoglobulin Dosage and Administration Form in CIDP and MMN
|
N/A | |
| Recruiting |
NCT04292834 -
A Registered Cohort Study of Immune-Mediated Neuropathies
|
||
| Terminated |
NCT03772717 -
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
N/A | |
| Completed |
NCT00278629 -
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
| Recruiting |
NCT02372149 -
IVIg for Demyelination in Diabetes Mellitus
|
Phase 4 |